Molecular pathology for classification of tumors and for efficacy prediction of qualified therapies is a rapidly expanding area. g., PARP inhibitor) being a consequence of data on the use of PARP inhibitors in BRCA1/2 mutation carriers with Superior breast most cancers (LoE 1b/GR B/In the pas